CDC Says BA.2.86 May Be More Capable Of Causing Infection In People Who Have Previously Had Covid-19 Or Who Have Received Covid-19 Vaccines
Portfolio Pulse from Benzinga Newsdesk
The CDC has reported that the BA.2.86 variant of Covid-19 may be more capable of causing infection in people who have previously had Covid-19 or who have received Covid-19 vaccines. This could potentially impact the effectiveness of vaccines produced by companies such as AstraZeneca (AZN), BioNTech (BNTX), Johnson & Johnson (JNJ), Moderna (MRNA), Novavax (NVAX), and Pfizer (PFE).
August 23, 2023 | 3:32 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The effectiveness of AstraZeneca's Covid-19 vaccine may be impacted by the BA.2.86 variant.
The news directly mentions the potential impact on the effectiveness of AstraZeneca's Covid-19 vaccine due to the new variant. This could lead to a decrease in demand for the vaccine, negatively impacting the company's stock.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
The effectiveness of BioNTech's Covid-19 vaccine may be impacted by the BA.2.86 variant.
The news directly mentions the potential impact on the effectiveness of BioNTech's Covid-19 vaccine due to the new variant. This could lead to a decrease in demand for the vaccine, negatively impacting the company's stock.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
The effectiveness of Johnson & Johnson's Covid-19 vaccine may be impacted by the BA.2.86 variant.
The news directly mentions the potential impact on the effectiveness of Johnson & Johnson's Covid-19 vaccine due to the new variant. This could lead to a decrease in demand for the vaccine, negatively impacting the company's stock.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
The effectiveness of Moderna's Covid-19 vaccine may be impacted by the BA.2.86 variant.
The news directly mentions the potential impact on the effectiveness of Moderna's Covid-19 vaccine due to the new variant. This could lead to a decrease in demand for the vaccine, negatively impacting the company's stock.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
The effectiveness of Novavax's Covid-19 vaccine may be impacted by the BA.2.86 variant.
The news directly mentions the potential impact on the effectiveness of Novavax's Covid-19 vaccine due to the new variant. This could lead to a decrease in demand for the vaccine, negatively impacting the company's stock.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
The effectiveness of Pfizer's Covid-19 vaccine may be impacted by the BA.2.86 variant.
The news directly mentions the potential impact on the effectiveness of Pfizer's Covid-19 vaccine due to the new variant. This could lead to a decrease in demand for the vaccine, negatively impacting the company's stock.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100